BLAINJECTIONINJECTABLEPriority Review
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
259
Data completeness
6/8 — Strong
Priority Review
IMFINZI (durvalumab) by AstraZeneca is programmed death ligand-1 antagonists [moa]. First approved in 2017.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMFINZI (durvalumab) is a monoclonal antibody that blocks Programmed Death Ligand-1 (PD-L1), enabling the immune system to recognize and attack cancer cells. It is administered by injection and is indicated for multiple solid tumors where it enhances anti-tumor immunity. The drug represents a key checkpoint inhibitor in the immuno-oncology landscape.
$0.025BPart D
PeakIMFINZI is at peak commercial maturity with moderate Part D penetration; commercial teams are focused on market consolidation and defending against competitive incursion in the PD-L1 space.
Mechanism of Action
Programmed Death Ligand-1 Antagonists
Pharmacologic Class:
Programmed Death Ligand-1 Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (259)
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Started Jan 2027
430 enrolled
Limited Stage Small-Cell Lung Cancer
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
Started Sep 2026
52 enrolled
Non-small Cell Lung Cancer
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
Started Sep 2026
33 enrolled
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Started Jul 2026
101 enrolled
Esophagogastric Adenocarcinoma
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
Started Jun 2026
50 enrolled
Extensive-stage Small-cell Lung Cancer
Worked on IMFINZI at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.